Castle Biosciences (CSTL) Cash from Operations (2018 - 2026)

Castle Biosciences has disclosed Cash from Operations across 9 years of filings, most recently posting 22129000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 22129000.0, down 266.62% year-over-year; the trailing twelve-month figure through Mar 2026 was 48254000.0 (down 26.51% YoY), and the FY2025 annual result was 64347000.0, down 0.8% from the prior year.
• Cash from Operations came in at 22129000.0 for Q1 2026 at Castle Biosciences, down from 26931000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 26931000.0 in Q4 2025 to a low of 25439000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 3786000.0 (2023), against an average of 3517823.53.
• Across the five-year window, Cash from Operations tumbled 490.2% in 2022 and jumped 733.86% in 2024, its largest moves.
• Castle Biosciences' Cash from Operations stood at 6000000.0 in 2022, then soared by 409.78% to 18587000.0 in 2023, then jumped by 31.09% to 24365000.0 in 2024, then gained by 10.53% to 26931000.0 in 2025, then slumped by 182.17% to 22129000.0 in 2026.
• The last three Cash from Operations figures came in at 22129000.0 (Q1 2026), 26931000.0 (Q4 2025), and 22631000.0 (Q3 2025), per Business Quant data.